Claims
- 1. A compound having the following structure:
- 2. The compound of claim 1 wherein m is 1 and n is 0, 2 or 3.
- 3. The compound of claim 1 wherein m is 2, 3 or 4 and n is 1.
- 4. The compound of claim 1 wherein one of p or q is 2, or both p and q are 2.
- 5. The compound of claim 1 wherein X is O.
- 6. The compound of claim 1 wherein X is NH or NR.
- 7. The compound of claim 1 wherein R1 and R3 are amino acid side chain moieties.
- 8. The compound of claim 1 wherein R2 is an amino acid side chain derivative.
- 9. A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
- 10. A method of preventing or suppressing an immune response or immune mediated response of an animal, comprising administering to said animal an effective amount of a compound having the following structure:
- 11. The method of claim 10 wherein said animal suffers from or is at risk of suffering from an autoimmune disease.
- 12. The method of claim 10 wherein said animal suffers from or is at risk of suffering from an inflammatory disease.
- 13. The method of claim 10 wherein said animal suffers from or is at risk of suffering from graft-versus-host disease.
- 14. The method of claim 10 wherein said animal will undergo or has undergone an allogeneic transplant.
- 15. The method of claim 10 wherein said animal will undergo or has undergone an xenogeneic transplant.
- 16. A method for inhibiting the proliferation of lymphocytes, comprising administering to an animal an effective amount of a compound having the following structure:
- 17. A method for enhancing graft survival following transplant, comprising administering to an animal previous to, concurrently with, or subsequent to a transplant procedure an effective amount of a compound having the following structure:
- 18. The method of claim 17 wherein said transplant is an allogeneic transplant.
- 19. The method of claim 17 wherein said transplant is an xenogeneic transplant.
- 20. A method for reducing interleukin-2 secretion from lymphocytes, comprising administering to an animal an effective amount of a compound having the following structure:
- 21. A method for inhibiting induction of CD25 or CD154 on lymphocytes following lymphocyte stimulation, comprising administering to an animal an effective amount of a compound having the following structure:
- 22. A method for inducing anergy or apoptosis in activated T-cells while maintaining overall T-cell counts, comprising administering to an animal a dosage of a compound having the following structure:
- 23. A method for inducing immune system tolerance to an antigen, comprising administering to an animal a dosage of a compound having the following structure:
- 24. A method for reducing secretion of tumor necrosis factor-alpha, comprising administering to an animal a dosage of a compound having the following structure:
- 25. A method for inhibiting the cell cycle of an activated T-cell prior to S-phase entry, comprising administering to an animal a dosage of a compound having the following structure:
- 26. The method of any one of claim 10, 16, 17, 20, 21, 22, 23, 24, or 25 wherein m is 1
- 27. The method of any one of claim 10, 16, 17, 20, 21, 22, 23, 24, or 25 wherein m is 2, 3 or 4.
- 28. The method of any one of claim 10, 16, 17, 20, 21, 22, 23, 24, or 25 wherein n is 1.
- 29. The method of any one of claim 10, 16, 17, 20, 21, 22, 23, 24, or 25 wherein n is 0, 2 or 3.
- 30. The method of any one of claim 10, 16, 17, 20, 21, 22, 23, 24, or 25 wherein p and q are both 1.
- 31. The method of any one of claim 10, 16, 17, 20, 21, 22, 23, 24, or 25 wherein one of p or q is 2, or both p and q are 2.
- 32. The method of any one of claim 10, 16, 17, 20, 21, 22, 23, 24, or 25 wherein X is O.
- 33. The method of any one of claim 10, 16, 17, 20, 21, 22, 23, 24, or 25 wherein X is NH or NR.
- 34. The method of any one of claim 10, 16, 17, 20, 21, 22, 23, 24, or 25 wherein R1, and R3 are the same or different and independently an amino acid side chain moiety.
- 35. The method of claim 34 wherein R1 and R3 are both —CH(CH3)2.
- 36. The method of any one of claim 10, 16, 17, 20, 21, 22, 23, 24, or 25 wherein R2 is an amino acid side chain derivative.
- 37. The method of claim 36 wherein R2 is ═CHCH3.
- 38. The method of any one of claim 10, 16, 17, 20, 21, 22, 23, 24, or 25 wherein the optional double bond is present.
- 39. The method of claim 38 wherein the double bond is in the trans-configuration.
- 40. The method of any one of claim 10, 16, 17, 20, 21, 22, 23, 24, or 25 wherein the compound is FR901228.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] The present invention claims priority to U.S. Provisional Application No. 60/169,731, filed on Dec. 8, 1999 and U.S. Provisional Application No. 60/193,582, filed Mar. 30, 2000.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60169731 |
Dec 1999 |
US |
|
60193582 |
Mar 2000 |
US |